Evidence map›Paper›PMID 41258298›Full record

ArticleNature communications2025

Improved analysis of in vivo drug combination experiments with a comprehensive statistical framework and web-tool.

Rafael Romero-Becerra, Zhi Zhao, Daniel Nebdal, Elisabeth Müller, Helga Bergholtz, Jens Henrik Norum, Tero Aittokallio

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rafael Romero-BecerraDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. r.r.becerra@medisin.uio.no.ORCID http://orcid.org/0000-0003-3935-2647
Zhi ZhaoDepartment of Biostatistics, Faculty of Medicine, Oslo Centre for Biostatistics and Epidemiology (OCBE), University of Oslo, Oslo, Norway.ORCID http://orcid.org/0000-0003-2325-1438
Daniel NebdalDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
Elisabeth MüllerDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0002-0686-9503
Helga BergholtzDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-0999-1106
Jens Henrik NorumDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.ORCID http://orcid.org/0000-0003-2689-7154
Tero AittokallioDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. t.a.aittokallio@medisin.uio.no.ORCID http://orcid.org/0000-0002-0886-9769

Funding

Kreftforeningen (Norwegian Cancer Society) 216104Kreftforeningen (Norwegian Cancer Society) 273810Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2020026Ministry of Health and Care Services | Helse Sør-Øst RHF (Southern and Eastern Norway Regional Health Authority) 2023105
6 · The paper itself

Abstract

Drug combination therapy is often required to overcome the limited benefits of monotherapy in cancer treatment. While several tools exist for in vitro drug synergy screening and assessment, there is a lack of integrated methods for statistical analysis of in vivo combination experiments. To fill this gap, we present SynergyLMM, a comprehensive modeling and design framework for evaluating drug combination effects in preclinical in vivo studies. Unlike other methods, SynergyLMM accommodates complex experimental designs, including multi-drug combinations, and offers practical options for statistical analysis of both synergy and antagonism through longitudinal drug interaction analysis, including model diagnostics and statistical power analysis. These functionalities allow researchers to optimize study designs and determine an appropriate number of animals and follow-up time points required to achieve sufficient synergy and statistical power. SynergyLMM is implemented as an easy-to-use web-application, making it widely accessible for researchers without programming skills. We demonstrate the versatility and added value of SynergyLMM through its applications to various experimental setups and treatment experiments with chemo-, targeted- and immunotherapy. These case studies showcase its potential to improve robustness, statistical rigor and consistency of preclinical drug combination results, enabling a faster and safer transition from preclinical to clinical testing.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsAnimalsDrug CombinationsDrug SynergismDrug Therapy, CombinationHumansInternetMiceNeoplasmsResearch DesignSoftwareDrug Combinations

Identifiers

PMID41258298
PMCPMC12630691

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.